VDT PACE effective in relapsed, refractory multiple myeloma

December 7, 2017

(HealthDay)—For heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM), bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide (VDT PACE) regimen and its modifications (VDT PACE-like regimens [VPLRs]) are effective, according to a study published online Oct. 25 in the American Journal of Hematology.

Arjun Lakshman, M.D., from the Mayo Clinic in Rochester, Minn., and colleagues analyzed outcomes of 141 patients with RRMM who received VPLRs between 2006 and 2017. Patients had received a median of four prior therapies, including (SCT) in 66.7 percent. Overall. 67.4 percent of patients received VDT PACE, 14.2 percent received VD PACE, and 18.4 percent received other VPLRs. A median of one cycle of VPLR was received by patients.

The researchers observed ≥ minimal , ≥ partial response (PR), and ≥ very good PR in 68.4, 54.4, and 10.3 percent of patients, respectively. Median progression-free and overall survival was 3.1 and 8.1 months, respectively. Overall, 82.3 percent of patients received some therapy after VPLR: 61.2 percent received systemic chemotherapy and 38.8 percent underwent SCT. For those who received SCT after VPLR, median overall survival was 15.1 months. For patients receiving VPLRs, age ≥60 years and revised international staging system III stage predicted shorter overall survival (hazard ratios, 2.3 and 2.4, respectively).

"VPLRs are effective in heavily pre-treated RRMM," the authors write. "In fit , SCT can be used to consolidate the response to VPLR."

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Combo Rx plus stem-cell tx ups PFS in multiple myeloma

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Combo Rx plus stem-cell tx ups PFS in multiple myeloma

April 7, 2017
(HealthDay)—Combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) plus stem-cell transplantation is associated with longer progression-free survival than RVD alone for adults with multiple myeloma, ...

Bortezomib ups response, survival in multiple myeloma

July 23, 2012
(HealthDay) -- For patients with newly diagnosed multiple myeloma (MM), induction treatment with a combination of bortezomib, doxorubicin, and dexamethasone (PAD) followed by bortezomib maintenance therapy improves complete ...

Ixazomib ups progression-free survival in multiple myeloma

April 28, 2016
(HealthDay)—For patients with relapsed, refractory, or relapsed and refractory multiple myeloma, ixazomib is associated with prolonged progression-free-survival, according to a study published in the April 28 issue of the ...

PFS up with obinutuzumab-based Tx in follicular lymphoma

October 5, 2017
(HealthDay)—For patients with follicular lymphoma, obinutuzumab-based immunochemotherapy is associated with longer progression-free survival than rituximab-based therapy, according to a study published online Oct. 4 in ...

Overall survival up for melanoma brain metastases

October 18, 2017
(HealthDay)—Overall survival (OS) for patients with melanoma brain metastases (MBM) has improved significantly since 2000, according to a study published online Oct. 12 in Cancer.

Chemo plus hyperthermia active in advanced pancreatic cancer

July 31, 2017
(HealthDay)—For patients with locally advanced or metastatic pancreatic carcinoma with malignant ascites, a combined systemic and intraperitoneal chemotherapy approach plus hyperthermia is well tolerated and active, according ...

Recommended for you

Magnetized wire could be used to detect cancer in people, scientists report

July 16, 2018
A magnetic wire used to snag scarce and hard-to-capture tumor cells could prove to be a swift and effective tactic for early cancer detection, according to a study by researchers at the Stanford University School of Medicine.

Researchers suggest new treatment for rare inherited cancers

July 16, 2018
Studying two rare inherited cancer syndromes, Yale Cancer Center (YCC) scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery, published today in Nature Genetics, suggests ...

Researchers map 'family trees' of acute myeloid leukemia

July 16, 2018
For the first time, a team of international researchers has mapped the family trees of cancer cells in acute myeloid leukaemia (AML) to understand how this blood cancer responds to a new drug, enasidenib. The work also explains ...

Looking at the urine and blood may be best in diagnosing myeloma

July 13, 2018
When it comes to diagnosing a condition in which the plasma cells that normally make antibodies to protect us instead become cancerous, it may be better to look at the urine as well as the serum of our blood for answers, ...

Massive genome havoc in breast cancer is revealed

July 12, 2018
In cancer cells, genetic errors wreak havoc. Misspelled genes, as well as structural variations—larger-scale rearrangements of DNA that can encompass large chunks of chromosomes—disturb carefully balanced mechanisms that ...

Study shows biomarker panel boosts lung cancer risk assessment for smokers

July 12, 2018
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smokers, an international ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.